Yellow fever, although rare, is spreading rapidly in Africa and South America due to the lack of sufficient vaccine and treatment. Recently, a phase-1 clinical trial of a yellow fever antibody was conducted. This research aims at breaking down the effectiveness of the vaccine in combating yellow fever.

This clinical trial included 37 healthy participants, 27 in phase-1a, and 10 in phase-1b. During phase-1a, the participants were given a TY014, a fully-human monoclonal antibody. In phase-1b, the participants were given a combination of TY014 and placebo. The primary outcome was the onset of adverse events throughout the trial.

During phase-1a, TY014 dose escalation of up to 20 mg per kg body weight occurred in 22 of 27 participants. In phase-1a, adverse events occurred in 1 of 27 patients, and no adverse events were reported in the 10 participants who received a placebo. Throughout the trial, 1 adverse event occurred in participants who received TY104 and in 8 who received a placebo. Out of 5 participants who received the starting dose of 2 mg per kg TY014, none had detectable YF17d-204 (yellow fever).

The research concluded that the phase-1 trial of TY104 showed significant clinical benefits without any worrisome safety concerns. However, further research is required to recognize the antibody’s clinical efficacy.